CD19 and diffuse large B-cell lymphoma: In 2017, FDA approved CD19-directed CAR-T cells as a treatment for relapsed/refractory pediatric and young-adult diffuse large B cell lymphoma (DLBCL), indicating the success in monoclonal diseases and neoplastic cells with the same target antigen [16, 39].